PT - JOURNAL ARTICLE AU - Tiril Hillestad AU - Tord Hompland AU - Christina S. Fjeldbo AU - Vilde E. Skingen AU - Unn Beate Salberg AU - Eva-Katrine Aarnes AU - Anja Nilsen AU - Kjersti V. Lund AU - Tina S. Evensen AU - Gunnar B. Kristensen AU - Trond Stokke AU - Heidi Lyng TI - MR Imaging Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer AID - 10.1101/2020.05.28.20114769 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.28.20114769 4099 - http://medrxiv.org/content/early/2020/05/29/2020.05.28.20114769.short 4100 - http://medrxiv.org/content/early/2020/05/29/2020.05.28.20114769.full AB - Tumor hypoxia levels range from mild to severe and have different biological and therapeutical consequences, but are not easily assessable in patients. We present a method based on diagnostic dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) that visualizes a continuous range of hypoxia levels in tumors of cervical cancer patients. Hypoxia images were generated using an established approach based on pixel-wise combination of the DCE-MRI parameters νe and Ktrans, reflecting oxygen consumption and supply, respectively. An algorithm to retrieve hypoxia levels from the images was developed and validated in 28 xenograft tumors, by comparing the MRI-defined levels with hypoxia levels derived from pimonidazole stained histological sections. We further established an indicator of hypoxia levels in patient tumors based on expression of nine hypoxia responsive genes. A strong correlation was found between these indicator values and the MRI-defined hypoxia levels in 63 patients. Chemoradiotherapy outcome of 74 patients was most strongly predicted by moderate hypoxia levels, whereas more severe or milder levels were less predictive. By combining gene expression profiles and MRI-defined hypoxia levels in cancer hallmark analysis, we identified a distribution of levels associated with each hallmark; oxidative phosphorylation and G2/M checkpoint were associated with moderate hypoxia, and epithelial-to-mesenchymal transition and inflammatory responses with significantly more severe levels. At the mildest levels, interferon response hallmarks, together with stabilization of HIF1A protein by immunohistochemistry, appearred significant. Thus, our method visualizes the distribution of hypoxia levels within patient tumors and has potential to distinguish levels of different prognostic and biological significance.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational study. The study was approved by the Regional Committee for Medical Health Research Ethics in southern Norway, and written informed consent was attained from all patients.Funding StatementThe South-Eastern Norway Regional Health Authority (Grant No 2015020) and The Norwegian Cancer Society (Grant No 107438 and 182451).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Regional Committee for Medical Health Research Ethics in southern Norway, and written informed consent was attained from all patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available at request. The gene expression data have been deposited to the GEO repository; GSE72723 (patient data), GSE147384 (cell line data).